Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Oct;17(4):1622-1644.
doi: 10.1007/s13311-020-00944-0. Epub 2020 Oct 23.

Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation

Ian O Bledsoe  1 , Aaron C Viser  2 , Marta San Luciano  2
Affiliations
Review

Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation

Ian O Bledsoe et al. Neurotherapeutics. 2020 Oct.

Abstract

Dystonia is a complex disorder with numerous presentations occurring in isolation or in combination with other neurologic symptoms. Its treatment has been significantly improved with the advent of botulinum toxin and deep brain stimulation in recent years, though additional investigation is needed to further refine these interventions. Medications are of critical importance in forms of dopa-responsive dystonia but can be beneficial in other forms of dystonia as well. Many different rehabilitative paradigms have been studied with variable benefit. There is growing interest in noninvasive stimulation as a potential treatment, but with limited long-term benefit shown to date, and additional research is needed. This article reviews existing evidence for treatments from each of these categories. To date, there are many examples of incomplete response to available treatments, and improved therapies are needed.

Keywords: Dystonia; botulinum toxin; deep brain stimulation; neuromodulation; rehabilitation.

PubMed Disclaimer

Similar articles

  • Therapeutic advances in dystonia.
    Albanese A, Romito LM, Calandrella D. Albanese A, et al. Mov Disord. 2015 Sep 15;30(11):1547-56. doi: 10.1002/mds.26384. Epub 2015 Aug 24. Mov Disord. 2015. PMID: 26301801 Review.
  • Therapeutic challenges in dystonia.
    Kartha N. Kartha N. Neurol Clin. 2010 Nov;28(4):927-40. doi: 10.1016/j.ncl.2010.03.020. Epub 2010 Jul 14. Neurol Clin. 2010. PMID: 20816271 Review.
  • [Diagnosis and treatment of dystonia].
    Kaji R, Sato K, Sako W, Goto S. Kaji R, et al. Rinsho Shinkeigaku. 2008 Nov;48(11):844-7. doi: 10.5692/clinicalneurol.48.844. Rinsho Shinkeigaku. 2008. PMID: 19198096 Review. Japanese.
  • Treatment of dystonia.
    Adam OR, Jankovic J. Adam OR, et al. Parkinsonism Relat Disord. 2007;13 Suppl 3:S362-8. doi: 10.1016/S1353-8020(08)70031-2. Parkinsonism Relat Disord. 2007. PMID: 18267265 Review.
  • Medical treatment of dystonia.
    Jankovic J. Jankovic J. Mov Disord. 2013 Jun 15;28(7):1001-12. doi: 10.1002/mds.25552. Mov Disord. 2013. PMID: 23893456 Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Bell SA, Tudur SC. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis. 2014;9:170. - PMC - PubMed
    1. Jinnah HA, Albanese A, Bhatia KP, Cardoso F, Da Prat G, de Koning TJ, et al. Treatable inherited rare movement disorders. Mov Disord. 2018;33(1):21–35. - PMC - PubMed
    1. Anagianni S, Tuschl K. Genetic Disorders of Manganese Metabolism. Curr Neurol Neurosci Rep. 2019;19(6):33. - PMC - PubMed
    1. Bandmann O, Weiss KH, Kaler SG. Wilson's disease and other neurological copper disorders. Lancet Neurol. 2015;14(1):103–13. - PMC - PubMed
    1. Mochel F, Hainque E, Gras D, Adanyeguh IM, Caillet S, Héron B, et al. Triheptanoin dramatically reduces paroxysmal motor disorder in patients with GLUT1 deficiency. Journal of neurology, neurosurgery, and psychiatry. 2016;87(5):550–3. - PMC - PubMed

MeSH terms